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R ecent evidence indicates that the renin-angiotensin system (RAS) plays critical roles in the development of the hematopoietic system [1] [2] [3] [4] and hematopoiesis. [5] [6] [7] Components of the RAS, including angiotensinogen, angiotensin II (Ang II), angiotensin 1 to 7 (Ang [1] [2] [3] [4] [5] [6] [7] ), angiotensin-converting enzyme, angiotensin-converting enzyme 2, angiotensin receptor type 1a (AT 1 R), AT 2 R are all present in bone marrow (BM) cells. 8, 9 Several studies have shown that angiotensin-converting enzyme inhibitors and AT 1 R/AT 2 R antagonists induce abnormal hematopoiesis suggesting that RAS regulates hematopoiesis through angiotensin receptors. 5, 10 In addition, Ang II and Ang (1) (2) (3) (4) (5) (6) (7) have been demonstrated to influence proliferation of hematopoietic progenitors and facilitate early recovery from mild myelosuppression. 11, 12 Consistent with these are our previous studies demonstrating increases in BM proinflammatory cells and a decrease in endothelial progenitor cells in chronic Ang II-induced hypertension. 13 These observations led us to propose that Ang II would exert a profound influence in hematopoietic stem cell (HSC) at the BM level. Understanding how Ang II regulates HSC would be critical as various BM originated hematopoietic cells have been shown to contribute to initiation and progress of hypertension [14] [15] [16] [17] and hypertension-associated diseases, such as cardiac infarction and arthrosclerosis. 18, 19 More than 1 million HSC transplantation (HSCT) were performed around the world to correct a variety of BM deficiencies. 20 During or after HSCT, immunosuppressive drugs such as cyclosporine A are widely used to minimize the risk of graft rejection and to increase the engraftment efficacy. 21 However, their clinical use is frequently associated with 2-to 5-fold increased Ang II level in the serum and kidney, resulting in systemic and renal vasoconstriction that leads to hypertension. [22] [23] [24] Considering this side effect of immune suppressors and prevalence of hypertension in public, it is Abstract-Emerging evidence indicates that differentiation and mobilization of hematopoietic cell are critical in the development and establishment of hypertension and hypertension-linked vascular pathophysiology. This, coupled with the intimate involvement of the hyperactive renin-angiotensin system in hypertension, led us to investigate the hypothesis that chronic angiotensin II (Ang II) infusion affects hematopoietic stem cell (HSC) regulation at the level of the bone marrow. Ang II infusion resulted in increases in hematopoietic stem/progenitor cells (83%) and long-term HSC (207%) in the bone marrow. Interestingly, increases of HSCs and long-term HSCs were more pronounced in the spleen (228% and 1117%, respectively). Furthermore, we observed higher expression of C-C chemokine receptor type 2 in these HSCs, indicating there was increased myeloid differentiation in Ang II-infused mice. This was associated with accumulation of C-C chemokine receptor type 2 + proinflammatory monocytes in the spleen. In contrast, decreased engraftment efficiency of GFP + HSC was observed after Ang II infusion. Time-lapse in vivo imaging and in vitro Ang II pretreatment demonstrated that Ang II induces untimely proliferation and differentiation of the donor HSC resulting in diminished HSC engraftment and bone marrow reconstitution. We conclude that (1) chronic Ang II infusion regulates HSC proliferation, mediated by angiotensin receptor type 1a, (2) Ang II accelerates HSC to myeloid differentiation resulting in accumulation of C-C chemokine receptor type 2 + HSCs and inflammatory monocytes in the spleen, and (3) Ang II impairs homing and reconstitution potentials of the donor HSCs. These observations highlight the important regulatory roles of Ang II on HSC proliferation, differentiation, and engraftment. (Hypertension. 2016;67:574-584.
critical to understand the role of RAS, especially the potent effector Ang II on HSC homing and engraftment to enhance HSCT efficiency. Engraftment of the donor-derived HSC in lethally irradiated recipients involves dynamic and multistep processes. 25 The donor HSCs recruited to the BM go through transmarrow migration and lodge in the HSC niche (HSC homing). Once the HSC arrives to the niche, its expansion is orchestrated by a complex interplay of niche cells, cytokines, and adhesion molecules in the microenvironment. 26, 27 Therefore, arrival of HSCs to the HSC niche is critical for efficient reconstitution of hematopoiesis. Our second goal in this study was to know if Ang II plays any important role in HSC homing and engraftment. Taken together, it is of extreme importance to understand how Ang II affects HSC regulation to enhance treatment of hypertension and HSCT. Thus, our objectives in this study were (1) to determine the effects of Ang II on proliferation and differentiation of the most primitive HSC in vivo and (2) to investigate whether Ang II affects HSC engraftment efficiency.
Methods

Mice and Ang II Infusion
Male C57BL6 mice (2-3 months old) were purchased from Charles River Laboratories. Human ubiquitin C promoter driven GFP (UBC-GFP) and CX3CR1 GFP/GFP mice were originally purchased from Jackson Laboratory and maintained at the University of Florida. The latter mice were bred with C57BL6/J mice to generate CX3CR1 +/GFP animals. Osmotic minipumps (1004, ALZAT Corporation) were loaded either with Ang II (Bachem) dissolved in 0.9% saline (wt/vol) or with saline alone. Ang II was delivered at a dose of 1000 ng·kg −1 ·min −1 . Pumps were designed to administer Ang II or saline for at least 28 days, which were implanted subcutaneously into the dorsum. In some experiments, osmotic pumps were replaced at the third week for constant saline/Ang II infusion. Losartan (Sigma-Aldrich) was administered daily by intraperitoneal injection (20 mg·kg −1 ·day −1 ) All experimental procedures performed on animals were in accordance with the University of Florida's Institutional Animal Care and Use Committee.
Video and Statistical Analysis
All videos were first captured using Volocity 5.5 and further processed and edited with Apple iMovie and Sony Vegas Pro 9.0. Statistical significance was determined by Student's t test using Prism 5 (Graphad). P values were designated as follows: *P≤0.05, **P≤0.01, and ***P≤0.001. All values in the data are mean±SEM. All experimental protocols and methods are available in the online-only Data Supplement. Figure 1C and 1D) that has been shown to be normally quiescent but possesses life-long hematopoietic repopulation potentials. 28, 29 We observed 207% increase of LT-HSC in the BM, which was also attenuated by cotreatment with losartan ( Figure 1G and 1H). These data indicate that chronic Ang II infusion resulted in an increase in HSC proliferation.
Next, we examined the levels of HSCs in the spleen. Interestingly, Ang II treatment resulted in 22% increase in total splenocytes (Figure 2A ), 228% increase in HSC ( Figure 2B and 2C), and 1117% increase in LT-HSC in the spleen of Ang II mice ( Figure 2D and 2E). These increases were attenuated by cotreatment with losartan. This demonstrates a significant increase of extramedullary hematopoietic activity in the spleen of Ang II-treated animals.
Ang II Regulates HSC Differentiation
We investigated if the expression levels of AT 1 R changed in HSPC and LT-HSC in Ang II-treated animals. We observed Figure 3A and 3B) . Next, we measured the C-C chemokine receptor type 2 (CCR2) levels to determine if Ang II caused differentiation of HSCs into further differentiated progenitors. A recent study showed that the CCR2 level in HSC is a critical marker for the initiation of HSC to myeloid differentiation and that CCR2 + HSCs are the intermediate HSC (HSC) with no LT reconstitution potentials. 30 FACS analysis showed that CCR2 + HSC populations are markedly increased in both BM and spleen of Ang II-infused animals, showing Ang II acts as an important initiator of HSC differentiation ( Figure 3C ).
Because the CCR2 + HSC is thought to be the most upstream contributor of myelopoiesis, 30 hi ) were analyzed and further gated for CCR2, we found that the number of monocytes and their CCR2 expressions were consistently increased in Ang II-infused mice. This suggests that Ang II affected downstream myeloid differentiation after HSC proliferation and that CCR2 expression was the key signal for BM to spleen mobilization. 31, 32 C57BL6 mice were reconstituted with HSPC from the BM of CX3CR1 +/GFP mice to determine the origin of increased myeloid cells in the BM and spleen ( Figure 5A ). We observed an increase of CX3CR1 +/GFP in Ang II-infused BM ( Figure 5B ). In addition, CX3CR1 +/GFP myeloid colonies were observed only in the Ang II-infused BM (arrows in the BM). Furthermore, there was significant accumulation of CX3CR1 +/GFP cells in the spleen with marked increase of round cells with typical monocyte morphology primarily located in the marginal zone of the spleen (arrows in the spleen). The result suggests that accumulation of myeloid/ monocyte cells in the BM and spleen originated from the BM HSCs.
Aberrant Engraftment of HSC in Ang II-Treated Mice
We next determined if effects of Ang II on proliferation, differentiation, and mobilization of HSC adversely affected engraftment of HSC into the BM in the HSCT setting. Homing and engraftment of HSC into the BM were compared between the saline-/Ang II-infused groups that are lethally irradiated by 2 different methods. At first, we injected the minimal survival number of HSPC from UBC-GFP mice (200 GFP + SKL cells, determined from a separate pilot study) with 2×10 5 whole BM cells into saline or Ang II (1000 ng·kg −1 ·min −1 ) infused and lethally irradiated mice. Survival rates of the chimeric mice were monitored >30 days for engraftment success. Only 58% of the Ang II-infused hypertension mice survived, whereas all salineinfused control mice were rescued ( Figure 6A ). This was associated with a noticeable reduction in engraftment of the donor HSC-derived GFP + cells (24%-50% compared with control), which was more prominent at the early engraftment stage of HSC (day 7) than the later ( Figure 6B ).
Second, we used a time-lapse imaging technique of the mouse tibial bone to directly track the HSC engraftment over time in saline-and Ang II-infused mice. 33 In salineinfused control group, individual HSCs that developed into colonies at the later time points were found mainly near the endosteum (Movie S1 in the online-only Data Supplement), where osteoblasts and other microenvironmental cells are enriched to support HSC. 25, 34, 35 These GFP + SKL cells started to engraft and actively expand in the osteoblastic HSC niche within 48 hours of injection, which is a critical hallmark of functional HSC ( Figure 6D ). 26 In contrast, GFP + SKL cells in Ang II-treated animals did not localize to the HSC niche and rarely formed proliferative colonies, suggesting that most HSCs were further differentiated and lost the engraftment potential ( Figure 6E ; Movie . Because extramedullary hematopoiesis in the spleen commonly occurs in lethally irradiated mice to facilitate hematopoietic recovery, 6 we examined the spleen of these 2 groups to find out that there was a statistically significant reduction in the number of colony-forming unit-spleen in Ang II-infused mice ( Figure 6F and 6G) . Furthermore, there was a marked decreases of the GFP + cells in the spleens of these mice demonstrating that overall engraftment of Ang II-infused mice was inefficient compared with saline-treated controls ( Figure 6H ).
Proliferation and Differentiation of HSC Result in Decreased Engraftment in Ang II-Infused Mice
To further investigate how HSCs engraft differently in these 2 groups, we first used a BrdU label retaining assay to track slow cycling HSCs that maintained stemness in saline-or Ang II-infused mice ( Figure 7A) . 36 Although many BrdU retaining HSCs were observed near the osteoblastic HSC niche of the saline-treated animals, few BrdU retaining cells were observed at the same area in Ang II-infused animals ( Figure 7B ). In vivo imaging of donor HSCs 18 hours after cell injection also indicated that there was early cell division of HSC in Ang II-treated mice (Figure 7C and 7D ; Movie S2 in the online-only Data Supplement). Although most of the transplanted HSCs in saline-infused mice remained as single cells at 18 hours after injection, ≈1 of 4 cells in Ang II-infused mice were observed as dividing cells ( Figure 5E ). Donor-derived SKL cells analyzed 10 days after injection indicated that there was a significant decrease of remaining HSCs in Ang II-infused animals ( Figure 7F ). Taken together, the results suggest that Ang II has adverse effects on HSC homing and engraftment because of untimely proliferation and early differentiation before reaching to the HSC niche.
Ang II Directly Affects LT Reconstitution Potential of HSC
To exclude the possibility that hemodynamic changes or any other indirect in vivo effects from systemic Ang II infusion influenced the engraftment efficiency, we incubated GFP + Lin − BM cells with or without Ang II for 18 hours in vitro, sorted and injected SKL cells (GFP + HSPC) into lethally irradiated animals ( Figure 8A ). The recipients were all normotensive and the GFP + HSPC were exposed to Ang II only in vitro before injection. The early survival rate of recipients that received Ang II-exposed HSPC was much lower than the control (40% versus 90%, Figure 8B ). The rate of hematopoiesis from Ang II-exposed HSPC was also significantly lower, confirming the direct effect of Ang II on HSC engraftment ( Figure 8C ). In addition, we observed poor BM reconstitution and a significant decrease of SKL cells in mice that received Ang II-exposed HSPC ( Figure 8D ). We performed serial transplantation of SKL cells from the first recipients to further test whether Ang II truly affected the LT reconstitution potential of the HSC. 29 Although the control HSPC still maintained the strong reconstitution potential in the secondary recipients, the Ang II-exposed HSPC failed to restore hematopoiesis and GFP + peripheral blood disappeared completely within 8 weeks in the secondary recipients ( Figure 8D ). Ki67 staining showed that more HSPCs were in active phases of the cell cycle when exposed to Ang II in vitro, confirming the previous result of untimely proliferation observed in Ang II-infused animals. The results indicate that Ang II directly and negatively affects LT reconstitution potential of HSC.
Discussion
The most significant finding of this study is that Ang II has profound influence on the compositions of HSC and myeloid progenitors. Ang II directly induced HSPC/LT-HSC proliferation and CCR2 + monocytes accumulation in the BM and spleen, while impairing homing and engraftment of HSC in the HSCT setting. We propose that these actions contribute to hypertensive effects of Ang II and suggest that controlling the RAS activity should be considered before HSCT to enhance engraftment efficacy of HSC. We observed that Ang II markedly increased numbers of both HSPC and quiescent LT-HSC, an effect attenuated by losartan, suggesting that upregulated AT 1 R transactivated various tyrosine and nontyrosine kinase receptors to carry out its pleiotropic effects for cell proliferation. 37 Our finding that Ang II has direct action on the BM HSC is supported by other reports showing the presence of AT 1 R in various BM cells and HSC. 7, 8, 10, 38 In addition, AT 1 Rmediated signaling is known to play critical roles for myeloid differentiation, 39, 40 highlighting the importance of Ang II in HSC regulation. Although direct Ang II actions are clearly evident from our data, its indirect effects on other regulatory microenvironmental cells in the BM such as osteoblasts 41, 42 and mesenchymal stem cells 43, 44 or extracellular matrix such as collagen, which is an important structural component of the HSC niche, 45, 46 cannot be ruled out at the present time. Most of the HSCs reside within the BM, while few are found in the spleen and circulation. These peripheral HSCs can contribute to extramedullary hematopoiesis in pathological conditions, such as infection, cardiovascular diseases, or irradiation. 19, 32, [47] [48] [49] Although HSCs in the spleen resemble BM HSCs because they are capable of multilineage reconstitution, 47 LT-HSCs that have life-long hematopoiesis potentials are thought to exist in the BM, based on observations that only the BM has all microenvironmental cells that constitute the HSC niche for LT-HSC maintenance. 27, 50 Interestingly, LT-HSCs that were extremely rare in the spleen of control mice were readily detectable in Ang II-infused mice, with an 8.6-fold increase in percentile and an 11-fold increase in absolute number (Figure 2) . We also observed accumulation of cells with myeloid lineage and inflammatory monocytes along with the increase of CCR2 + HSC. CCR2 is an important signal for recruiting hematopoietic cells to the inflammatory sites 31 and it could have played similar roles for mobilization of HSC to the spleen (Figures 3-5) . 32 In addition, we speculate that the oxidative stress from Ang II infusion could have induced CCR2 overexpression and myeloid-biased differentiation. 51, 52 Our study is unique in a way that it uses continuous time-lapse in vivo imaging at a single-cell resolution, allowing direct observation of functional bona fide HSC with 6 BM MNC from C56BL6 mice. B, The survival rate of the primary recipients that had either HSPC incubated with STEMSPAN media or HSPC incubated with media and Ang II (250 μg/mL) for 18 hours (n=10). C, GFP + peripheral blood (PB) reconstitution of each group on weeks 3 and 6. D, Serial transplantation assay using HSPC exposed to Ang II before injection. Ang II-exposed HSPC showed significantly lower BM engraftment and did not reconstitute peripheral blood in the second transplantation. E, Ki67 + HSPCs that are in active phases of the cell cycle after 18 hours in vitro culture with or without Ang II. *P≤0.05, **P≤0.01. Figure 6 ). Using this technology, we have shown that Ang II infusion significantly inhibited homing and engraftment of HSC into the BM HSC niche. In vivo imaging showed that many donor-derived HSC went through early proliferation possibly from the proliferative effect of Ang II through AT 1 Rmediated mean arterial pressure kinases and the JAK/STAT activation. 37 This untimely event resulted in a decrease of available HSC for engraftment in the BM osteoblastic HSC niche ( Figure 7) . As the microenvironmental signals that HSC receive from the niche are critical for efficient engraftment and proliferation, 27 this led to abnormal and inefficient engraftment of HSC in Ang II-treated recipients. Because in vitro exposure of Ang II to HSCs also negatively affected engraftment in normotensive recipients, the results highlight the direct and adverse role of Ang II for HSC engraftment potentials (Figure 8) .
We have summarized our conclusion in Figure 9 , describing the important dual roles of Ang II in HSC regulation. Although chronic Ang II infusion increased the numbers of HSCs leading to myeloid-biased differentiation in the BM and mobilization of CCR2 + HSCs/monocytes to the spleen, it also decreased engraftment efficiency of HSC in the lethally irradiated recipients because of early differentiation and undue proliferation before homing. It would be interesting to investigate the roles of increased myeloid progenitors and monocyte in the progress of Ang II-induced hypertension. There is a growing body of evidence that immune changes and increased inflammatory monocytes are the key to development of hypertension and cardiovascular diseases through vascular inflammation. 15, 53 In addition, our previous evidence has shown that neuroinflammation plays important roles in the development and establishment of neurogenic hypertension. 13, 54 On the basis of our present data, it is tempting to speculate that increases of HSC and myeloid progenitors in the BM and spleen would be critical to mobilization of these proinflammatory cells into the brain. 14, 55, 56 
Perspectives
Our study shows that Ang II has profound influence on BM and spleen HSCs, affecting their proliferation, differentiation, and engraftment efficiency. Considering that the level of circulating Ang II can change drastically in patients with hypertension, 57 these changes may similarly affect human BM and spleen, contributing to the progress of hypertension 16, 17 and hypertension-associated cardiovascular diseases. 18, 19, 30 Although we used the pressor dose to investigate immune changes in the animal model, the effects of Ang II on hematopoietic cells may vary depending on the dose and exposure time. Further study would be required to understand AT 1 R/ AT 2 R-mediated signalings that lead to immune changes in hypertension. The negative effects of Ang II on HSC engraftment and homing have significant clinical implications in HSCT, as Ang II-induced hypertension is one of the major side effects of immunosuppressive drugs used after allogeneic HSCT. 23 Angiotensin receptor blockers and angiotensinconverting enzyme inhibitors are commonly prescribed to treat hypertension in patients with HSCT 58 and our results
show that antihypertensive drugs should be carefully chosen for these patients. 59 There is no clinical data that has clearly addressed the impact of hypertension on HSCT success and patients survival. Thus, it would be relevant to undertake a retrospective study to determine the influence of high blood pressure in HSCT.
